Maravai LifeSciences (NASDAQ:MRVI) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Maravai LifeSciences (NASDAQ:MRVI) issued its quarterly earnings data on Thursday. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.06, FiscalAI reports. The business had revenue of $65.84 million during the quarter, compared to the consensus estimate of $53.00 million. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.29%.

Here are the key takeaways from Maravai LifeSciences’ conference call:

• Strong Q1 and upgraded outlook: Q1 revenue was $65.8M (41% YoY) with adjusted EBITDA of $20.3M, and management raised full-year revenue guidance to $205M–$215M and adjusted EBITDA to $30M–$32M.
• TriLink momentum: TriLink drove the quarter—72% of revenue, 65% YoY growth (15% base growth excluding CleanCap)—with >70 customers adopting ModTail and a GMP customer funnel expected to grow ~22% in 2026.
• Operational and cash improvements: Adjusted gross margin was 65.3%, the company generated $4.2M of free cash flow, repaid $50M of debt, and expects >$65M of annual EBITDA savings from restructuring.
• Cygnus remains profitable and strategically relevant, posting a 73.8% adjusted EBITDA margin, expanding into DNA quant/extraction kits and MockV products, and maintaining a 100% attach rate across 29 FDA/EMA‑approved CAR T/gene therapies.
• Timing and lumpiness risks remain—revenue can swing quarter-to-quarter due to large orders, and Q1 softness in China (distributor ordering timing) plus weaker academic demand could delay some recovery in APAC.

Maravai LifeSciences Trading Up 23.1%

Shares of MRVI stock traded up $0.91 during trading hours on Friday, hitting $4.85. 11,235,952 shares of the company’s stock traded hands, compared to its average volume of 1,994,654. The stock’s 50 day simple moving average is $3.33 and its 200 day simple moving average is $3.39. The stock has a market cap of $1.25 billion, a PE ratio of -6.83 and a beta of 0.62. Maravai LifeSciences has a 12 month low of $1.95 and a 12 month high of $4.95. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wall Street Zen raised shares of Maravai LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday. Finally, Wells Fargo & Company increased their price objective on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.70.

Hedge Funds Weigh In On Maravai LifeSciences

Large investors have recently modified their holdings of the business. Virtu Financial LLC bought a new position in shares of Maravai LifeSciences during the fourth quarter valued at $34,000. Insigneo Advisory Services LLC bought a new position in shares of Maravai LifeSciences during the fourth quarter valued at $34,000. Quantessence Capital LLC bought a new position in shares of Maravai LifeSciences during the third quarter valued at $31,000. Stifel Financial Corp bought a new position in shares of Maravai LifeSciences during the fourth quarter valued at $36,000. Finally, Jain Global LLC bought a new position in shares of Maravai LifeSciences during the fourth quarter valued at $36,000. Institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.